Nu Skin Enterprises Inc. Common Stock (NUS)

FairStock Score: 75/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $91 million in annual free cash flow (24.5% yield on market cap)
• High return on equity of 22.0% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.38, providing financial flexibility
• Attractive 3.2% dividend yield providing steady income returns
• FairStock composite score of 75/100 places it in the top tier across value, quality, and momentum factors

Concerns

• Revenue declining at 16.9% year-over-year signals potential demand weakness or market share loss

AI Analysis

Nu Skin Enterprises Inc. Common Stock is a micro-cap consumer defensive company valued at $371 million. The business generates $1.5 billion in annual revenue with a 1.0% net margin and $91 million in free cash flow. From a quality standpoint, Nu shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 2.8 in the grey zone. On valuation, the stock is deeply undervalued on a P/E basis at 2.4x, with offers a 78% margin of safety vs Graham Number of $35. Growth dynamics show revenue growing at -16.9% and profit growth of 140.1%. The 3.2% dividend yield adds an income component for patient holders. Our composite FairStock Score of 75/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates Nu's consistent 22% ROE at just 2x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $91 million in annual free cash flow (24.5% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the consumer defensive space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer